Eric Ende

Eric J.
Ende is the founder of Wellfit Holdings LLC.
Current positions include Chairman at Matinas BioPharma, Inc. since 2017, Director at Mount Sinai Innovation Partners, Director at Mesa Therapeutics, Inc., President at Ende Consulting Group, Inc. since 2009, and President at Ende Biomedical Consulting Group, Inc. since 2009.
Former roles include Chairman at Matinas BioPharma Holdings, Inc. from 2022 to 2025, Director at Amylin Pharmaceuticals, Inc., Director at Progenics Pharmaceuticals, Inc. from 2019 to 2020, Director at Genzyme Corp.
from 2010 to 2011, Independent Director at Avadel Pharmaceuticals Plc from 2018 to 2026, Director at NeuBase Therapeutics, Inc. from 2022 to 2023, and Research Analyst at Merrill Lynch, Pierce, Fenner & Smith, Inc. Education includes an undergraduate degree from Emory University in 1990, a doctorate from Icahn School of Medicine at Mount Sinai in 1994, and an MBA from The Leonard N Stern School of Business in 1997.